GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BGI Genomics Co Ltd (SZSE:300676) » Definitions » Research & Development

BGI Genomics Co (SZSE:300676) Research & Development : ¥513 Mil (TTM As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is BGI Genomics Co Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. BGI Genomics Co's Research & Development for the three months ended in Mar. 2024 was ¥106 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 was ¥513 Mil.


BGI Genomics Co Research & Development Historical Data

The historical data trend for BGI Genomics Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BGI Genomics Co Research & Development Chart

BGI Genomics Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 317.32 619.64 487.15 535.78 528.93

BGI Genomics Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 122.06 142.53 123.73 140.61 106.37

BGI Genomics Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥513 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BGI Genomics Co  (SZSE:300676) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


BGI Genomics Co Research & Development Related Terms

Thank you for viewing the detailed overview of BGI Genomics Co's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


BGI Genomics Co (SZSE:300676) Business Description

Traded in Other Exchanges
N/A
Address
21 Hongan Third Street, Dong, Huada Complex Park, Yantian District, Shenzhen, CHN, 518083
BGI Genomics Co Ltd is a China-based company principally engaged in the provision of genomic class diagnosis and research services through the application of biotechnology. It offers its services in various research areas, such as agriculture and food science, cancer research, metagenomics, reproductive health, biomarker discovery, and drug discovery. The company mainly provides services for domestic and overseas academic institutions hospitals, medical institutions and others.
Executives
Wang Jian Director
Liu Na Executives
Sun Ying Jun Director
Yin Ye Directors, executives
Du Yu Tao Directors, executives
Li Song Gang Supervisors
Hu Yu Jie Supervisors
Xu Qian Secretary Dong
Li Zhi Ping Executives
Chen Yi Qing Executives
Li Wen Qi Supervisors

BGI Genomics Co (SZSE:300676) Headlines

No Headlines